CureVac clinical trials

Acquired by BioNTech SE, Dec 3, 2025 · source ↗

The registry lists 18 studies whose lead sponsor is CureVac. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated May 29, 2026.

Before and after it joined BioNTech SE

First submitted before CureVac became part of BioNTech SE: 18
First submitted after CureVac became part of BioNTech SE: 0
Unclear, or no submission date: 0

By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.

Status

Completed: 11
Terminated: 4
Withdrawn: 2
Status unknown: 1

Phase

Phase 1: 12
Phase 2: 6
Phase 3: 4

Where

Germany: 13
Belgium: 5
Spain: 4
Switzerland: 3
Panama: 3
France: 3

Registry sponsor names on this page

CureVac18 studies

Something wrong with this grouping? Tell us on the BioNTech SE page.

Studies

Recruiting first, then most recently updated. Showing 18 of 18. All BioNTech SE studies →

Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)WithdrawnNCT07073183Phase 1
Sponsor listed in the registry: CureVac · First submitted before CureVac became part of BioNTech SE
Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or AstrocytomaCompletedNCT05938387Phase 1
Sponsor listed in the registry: CureVac · First submitted before CureVac became part of BioNTech SE
A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy AdultsCompletedNCT03713086Phase 1
Sponsor listed in the registry: CureVac · First submitted before CureVac became part of BioNTech SE
A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and OlderCompletedNCT04652102Phase 2/3
Sponsor listed in the registry: CureVac · First submitted before CureVac became part of BioNTech SE
A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19CompletedNCT04674189Phase 3
Sponsor listed in the registry: CureVac · First submitted before CureVac became part of BioNTech SE
A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19CompletedNCT04515147Phase 2
Sponsor listed in the registry: CureVac · First submitted before CureVac became part of BioNTech SE
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVSQIV in Healthy AdultsCompletedNCT05252338Phase 1
Sponsor listed in the registry: CureVac · First submitted before CureVac became part of BioNTech SE
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19CompletedNCT04449276Phase 1
Sponsor listed in the registry: CureVac · First submitted before CureVac became part of BioNTech SE
COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbiditiesTerminatedNCT04860258Phase 3
Sponsor listed in the registry: CureVac · First submitted before CureVac became part of BioNTech SE
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACCStatus unknownNCT03291002Phase 1
Sponsor listed in the registry: CureVac · First submitted before CureVac became part of BioNTech SE
A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19WithdrawnNCT04838847Phase 3
Sponsor listed in the registry: CureVac · First submitted before CureVac became part of BioNTech SE
RNActive® Rabies Vaccine (CV7201) in Healthy AdultsCompletedNCT02241135Phase 1
Sponsor listed in the registry: CureVac · First submitted before CureVac became part of BioNTech SE
Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy AdultsCompletedNCT02238756Phase 1
Sponsor listed in the registry: CureVac · First submitted before CureVac became part of BioNTech SE
Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)CompletedNCT00923312Phase 1/2
Sponsor listed in the registry: CureVac · First submitted before CureVac became part of BioNTech SE
Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory DiseaseCompletedNCT00831467Phase 1/2
Sponsor listed in the registry: CureVac · First submitted before CureVac became part of BioNTech SE
Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate CancerTerminatedNCT01817738Phase 1/2
Sponsor listed in the registry: CureVac · First submitted before CureVac became part of BioNTech SE
Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC)TerminatedNCT01915524Phase 1
Sponsor listed in the registry: CureVac · First submitted before CureVac became part of BioNTech SE
An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate CancerTerminatedNCT02140138Phase 2
Sponsor listed in the registry: CureVac · First submitted before CureVac became part of BioNTech SE